The collaboration will expand access to Alzheimer’s biomarker testing through mobile delivery to community centers, churches, and senior centers nationwide.
Lucent Diagnostics, a brand of Quanterix Corp, has partnered with Life Line Screening to offer blood-based biomarker testing for cognitive disease detection in community settings nationwide.
The partnership enables Life Line Screening to offer Lucent’s non-invasive blood-based biomarker tests through its mobile delivery model, with programs already underway in Florida, California, and Texas. Life Line Screening will provide testing opportunities at local venues including community centers, churches, and senior centers.
“Too many chronic conditions go undetected until they become life-altering events,” says Jim Waters, chief operating officer at Life Line Screening, in a release. “By partnering with Lucent Diagnostics, we’re able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably.”
According to the Alzheimer’s Association, an estimated 7 million Americans are living with Alzheimer’s disease today, with another 6-7 million experiencing symptoms of mild cognitive impairment.
Expanding Access Through Mobile Testing
Life Line Screening operates in the 48 contiguous states and hosts over 15,000 community events annually, providing infrastructure that reaches individuals in both major metropolitan areas and underserved rural regions. Test results can be shared with primary care physicians to facilitate early intervention and proactive lifestyle management for adults.
“Scientific rigor shouldn’t stop at the laboratory door. Through [Life Line Screening], Lucent Diagnostics is bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting,” says Zachary Fernandes, Quanterix general manager for Lucent Diagnostics, in a release.
Lucent Diagnostics was created in 2023 to deliver tools for earlier detection of cognitive disease. The company’s tests are powered by Simoa technology and designed to bridge the gap between research and clinical use.
Life Line Screening, established in 1993, has provided preventive health screenings to more than 11 million people and focuses on identifying asymptomatic risks for chronic conditions in community health settings.
ID 4680261 © Alexander Chelmodeev | Dreamstime.com
